Table: Santen Pharm 6-MTH group results (IFRS)
06/11/2025 06:31
Nov 6 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2025 Sep 30, 2024 Mar 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 137.88 146.40 294.00
(-5.8 pct) (+0.4 pct) (-2.0 pct)
Operating 17.92 23.87 44.00
(-25.0 pct) (-4.9 pct) (-6.1 pct)
Pretax
Net 13.94 18.77 34.00
(-25.7 pct) (-2.6 pct) (-6.2 pct)
EPS Basic 41.76 yen 52.88 yen 102.66 yen
EPS Diluted 41.70 yen 52.74 yen
Ann Div 36.00 yen 38.00 yen
-Q2 Div 19.00 yen 17.00 yen
-Q4 Div 19.00 yen 19.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T